Maria I. Colnaghi - Concepedia

Author

Maria I. Colnaghi

Fondazione IRCCS Istituto Nazionale dei Tumori

Also Known As

M I Colnaghi, M. I. COLNAGHI, M. I. Colnaghi, M. Ines COLNAGHI, M. Ines Colnaghi, M.I Colnaghi, M.I. Colnaghi, MARIA I. COLNAGHI, MARIA INES COLNAGHI, MI Colnaghi

207

Publications

5.8K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori University of Milan Alleanza Contro il Cancro

About

Maria I. Colnaghi is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	56	3K
2	Natural Sciences	6	6	410
3	Allergy	5	5	109
4	Biochemistry	3	3	170
5	Health Sciences	1	1	55

Maria I. Colnaghi

105

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity Silvia Miotti, Silvana Canevari, Sylvie Ménard, International Journal of Cancer	1987	317
Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Leslie R. Coney, Antonella Tomassetti, Leon Carayannopoulos, PubMed Immunocytochemical TechniqueImmunologyGlycobiologyPathologyImmunotherapy	1991	299
Prognostic significance of her‐2/<i>neu</i> expression in breast cancer and its relationship to other prognostic factors Franco Rilke, Maria I. Colnaghi, Natale Cascinelli, International Journal of Cancer Tumor BiologyBreast OncologyGood PrognosisMedicineImmunology	1991	260
Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Sylvie Ménard, Elda Tagliabue, Silvana Canevari, PubMed Breast OncologyImmunologyPathologyImmunotherapyTumor Biology	1983	230
Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to <i>HER2</i> Overexpression and Other Tumor Biologic Variables Sylvie Ménard, Pinuccia Valagussa, Silvana Pilotti, Journal of Clinical Oncology	2001	150
Prognostic Significance of the 67-Kilodalton Laminin Receptor Expression in Human Breast Carcinomas Stefania Martignone, S. Ménard, Rosaria Bufalino, JNCI Journal of the National Cancer Institute	1993	141
The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution Elena Ardini, Graziano Pesole, Elda Tagliabue, Molecular Biology and Evolution GeneticsMolecular BiologyMolecular GeneticsCellular PhysiologyProtein Synthesis	1998	136
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Sylvie Ménard, Gorana Tomasic, Patrizia Casalini, PubMed Breast OncologyImmunologyImmunoeditingPathologyImmune System	1997	128
Cellular and humoral immunity against human malignant melanoma Giuseppe Fossati, Maria I. Colnaghi, Giuseppe Della Porta, International Journal of Cancer ImmunoeditingImmunologyImmune RegulationImmunotherapeuticsDermatology	1971	120
Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients Giuliana Anna Porro, Sylvie Ménard, Elda Tagliabue, Cancer Breast OncologyImmunocytochemical TechniqueCarcinoma CellsImmunologyImmunoediting	1988	103

Page 1